| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 60.08 | 6.0% | 23.5% |
| Total Income | 60.08 | 6.0% | 23.5% |
| Expenditure | 44.08 | 9.2% | 19.9% |
| PBT | — | ||
| Net Profit | 0.71 | 22.4% | 138.2% |
| OPM | 3.18% | 0.23pp | 3.83pp |
| NPM | 1.18% | 0.16pp | 5.00pp |
| EPS | 0.02 | 100.0% | 150.0% |
Axogen, Inc. Reports Q3 2025 Revenue Up 23.5% to $60.1 Million
04 May 2026 · 4 May, 8:37 am
Summary
Axogen, Inc. reported a 23.5% increase in revenue for the third quarter of 2025, reaching $60.1 million. Gross margin improved to 76.6%, up from 74.9% in the same quarter of the previous year. Net income for the quarter was $0.7 million, a significant improvement from the net loss of $1.9 million in Q3 2024. The company has raised its full-year revenue guidance to at least 19% growth, or $222.8 million.
Key Highlights
- 1
Third quarter revenue was $60.1 million, a 23.5% increase compared to the third quarter of 2024.
- 2
Gross margin for the third quarter of 2025 was 76.6%, up from 74.9% for the third quarter of 2024.
- 3
Net income for the quarter was $0.7 million, or $0.01 per share, compared to a net loss of $1.9 million, or $0.04 per share for the third quarter of 2024.
- 4
Adjusted EBITDA was $9.2 million for the quarter, compared to $6.5 million for the third quarter of 2024.
- 5
The company raised its full year revenue guidance to at least 19% growth, or $222.8 million.
- 6
Cash and cash equivalents, restricted cash, and investments increased $3.9 million during the third quarter of 2025.
- 7
Expanded coverage and reimbursement for nerve repair for peripheral nerve injuries using synthetic conduits or allografts, increasing the total number of new lives covered in 2025 to approximately 18.1 million and bringing coverage amongst commercial payers to more than 64%.
Management Comments
Michael Dale
“Our third quarter performance reflects the continued maturation of the peripheral nerve repair market, with revenue growing 23.5% to $60.1 million and adjusted EBITDA of $9.2 million as we scale our commercial operations. New position statements from AAHS and ASRM, together with AAOMS guidelines recognizing nerve allografts as standard medical practice, and the addition of 1.1 million additional covered lives, validate our ongoing market development strategy. With double-digit growth across all markets and the expected completion of our Avance® Nerve Graft BLA in December, we’re advancing our mission to make peripheral nerve repair an expected standard of care.”
Informational and educational content only. Not investment advice.